Skip to main content
Andrew Gilman, MD, Pediatric Hematology & Oncology, Charlotte, NC

AndrewLGilmanMD

Pediatric Hematology & Oncology Charlotte, NC

Senior Medical Director PRA Health Sciences

Dr. Gilman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gilman's full profile

Already have an account?

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1988 - 1991
  • UPMC Children's Hospital of Pittsburgh
    UPMC Children's Hospital of PittsburghResidency, Pediatrics, 1985 - 1988
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1985
  • Pennsylvania State University
    Pennsylvania State UniversityBS, Summa Cum Laude, 1983

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2004 - 2025
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
  • Clinical Oncology Fellowship American Cancer Society, 1990
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi Anemia patient  
    Yeo CJ, Gilman AL, J Pediatr Hematol Oncol, 1/1/2014
  • Haploidentical Related Donor Hematopoietic Cell Transplantation in Children Using Megadoses of CliniMACS-selected CD34+ Cells and a Fixed CD3+ Dose  
    Dvorak CC, Gilman AL, Horn B, Oon C-Y, Dunn EA, Baxter-Lowe LA, Cowan MJ, Bone Marrow Transplantation, 1/1/2013
  • Adoptive immunotherapy with CMV-specific T cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections  
    Bao L, Cowan MJ, Dunham K, Horn B, McGuirk J, Gilman A, Lucas KG, J Immunother, 1/1/2012
  • Join now to see all

Abstracts/Posters

  • CD34-selected, T cell-depleted alternative donor stem cell transplantation for pediatric non-malignant diseases
    Eckrich MJ, Epstein S, Barnhart C, Oesterheld J, Grochowski D, Fuchs T, Cannon M, Lacaria M, Teplick A, Gilman A, Second Annual Pediatric Blood and Marrow Transplant Consortium at American Society of Pediatric Hematology/Oncology: New Frontiers in Allogeneic Stem Cell Transplant, 5/1/2014
  • A Comprehensive Safety Trial of Chimeric Antibody 14.18 with GM-CSF, IL-2 and Isotretinoin (ImmRx) in High-Risk Neuroblastoma Patients Following Myeloablative Therapy:...
    Ozkaynak MF, Gilman AL, Yu AL, London WB, Sondel PM, Smith M, Seeger R, Reynolds CP, Maris JM, Park JR, American Society of Clinical Oncology Meeting, 5/1/2014
  • CD34-selected, T cell-depleted alternative donor stem cell transplantation for children
    Gilman A, Eckrich M, Epstein S, Barnhart C, Oesterheld J, Grochowski D, Fukes T, Lacaria M, Cannon M, American Society of Hematology, 55th Annual Meeting, 12/1/2013
  • Join now to see all

Lectures

  • Graft Engineering – Building a Better Bone Marrow Transplant 
    Charlotte, NC - 3/1/2013
  • Role of Cytogenetics and Molecular Genetics in BMT 
    11/1/2008
  • Pulmonary Complications of Bone Marrow Transplantation 
    4/1/2007
  • Join now to see all